Liposome-encapsulated eribulin shows enhanced antitumor activity over eribulin for combination therapy with anti-PD-1 antibody.
Yuki NiwaKeito AdachiKimiyo TabataRyoga IshidaKoichiro HottaTomomi IshidaYuji ManoYoichi OzawaYukinori MinoshimaYasuhiro FunahashiTaro SembaPublished in: Molecular cancer therapeutics (2023)
Eribulin is a microtubule dynamics inhibitor with tumor microenvironment modulation activity such as vascular remodeling activity. Here, we investigated antitumor and immunomodulatory activities of eribulin and its liposomal formulation (eribulin-LF) as monotherapies or in combination with anti-PD-1 antibody. The antitumor activity of eribulin or eribulin-LF as monotherapy or in combination with anti-PD-1 antibody was examined in a P-glycoprotein-knockout 4T1 model. Eribulin and eribulin-LF showed stronger antitumor activity in immunocompetent mice compared with immunodeficient mice, indicating that they have immunomodulatory activity that underlies its antitumor activity. Combination therapy of eribulin and eribulin-LF with anti-PD-1 antibody showed antitumor activity, and the combination activity of eribulin-LF with anti-PD-1 antibody was observed at a lower dose and longer interval of administration compared with that using eribulin. To examine the immunomodulatory activity of eribulin and eribulin-LF and its underlying mechanisms, we performed flow cytometry, immunohistochemistry, and gene expression profiling. Immunohistochemistry and flow cytometry revealed that eribulin-LF increased microvessel density and intratumoral populations of cytotoxic T cells and natural killer cells rather than eribulin. Gene expression profiling demonstrated that eribulin-LF induces interferon-γ signaling. Furthermore, immunohistochemistry also showed that eribulin-LF increased infiltration of CD8-positive cells together with increased CD31-positive cells. Eribulin-LF also increased ICAM-1 expression, which is essential for lymphocyte adhesion to vascular endothelial cells. In conclusion, eribulin showed combination antitumor activity with anti-PD-1 antibody via immunomodulation due to its vascular remodeling activity, and the liposomal formulation showed improved antitumor activity over the standard formulation.
Keyphrases
- metastatic breast cancer
- phase ii
- combination therapy
- clinical trial
- flow cytometry
- endothelial cells
- genome wide
- open label
- type diabetes
- induced apoptosis
- escherichia coli
- gene expression
- dna methylation
- single cell
- randomized controlled trial
- oxidative stress
- cystic fibrosis
- poor prognosis
- cell proliferation
- staphylococcus aureus
- mass spectrometry
- copy number
- binding protein
- genome wide identification
- signaling pathway
- wild type
- high glucose